ArticleIranian journal of basic medical sciences2026
Fluoxetine attenuates UPR-activation, neuroinflammation, and oxidative stress in a nitroglycerin-induced rat model of migraine.
Article in Iranian journal of basic medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Migraine is a debilitating neurological disorder characterized by oxidative stress, neuroinflammation, and dysregulation of the unfolded protein response (UPR) in the brain. Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), has demonstrated neuroprotective properties, but its effects on UPR activation, neuroinflammation, and oxidative stress in migraine are not well defined. This study evaluates the effects of fluoxetine on UPR-related gene expression, inflammatory cytokines, and oxidative stress markers in a nitroglycerin (NTG)-induced chronic migraine rat model. Materials and Methods: Rats were divided into control, NTG-induced chronic migraine, and fluoxetine-treated groups. Behavioral light aversion was assessed. Trigeminal ganglion tissues were analyzed for expression of UPR-associated genes (Bip, XBP-1, CHOP) and inflammatory markers (IL-6, IL-1β, IL-10, NF-κB, TNF-α) using molecular techniques. Serum levels of oxidative stress indicators, including catalase (CAT), superoxide dismutase (SOD), malondialdehyde (MDA), and total antioxidant capacity (TAC), were measured. Results: Our results demonstrate that fluoxetine treatment effectively tempered the maladaptive UPR by modulating the expression of Bip, XBP-1, and CHOP. It also suppressed neuroinflammation by reducing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and enhancing the anti-inflammatory cytokine IL-10. Fluoxetine also counteracted oxidative stress by restoring the activity of antioxidant enzymes (SOD, CAT), reducing lipid peroxidation (MDA), and enhancing overall antioxidant capacity (TAC). Importantly, these positive biochemical changes were correlated with a significant reduction in light aversion behavior. Conclusion: Fluoxetine exerts protective effects in an NTG-induced migraine model by modulating UPR pathways, reducing neuroinflammation, and alleviating oxidative stress. These findings highlight its potential as a therapeutic agent targeting multiple pathways in migraine pathophysiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.